pocketful logo light
pocketful logo light
Granules India Ltd logo

Granules India Ltd

NSE: GRANULES BSE: 532482

₹909.30

(1.12%)

Mon, 14 Sept 2026, 07:15 pm

mtf coin illustrationMTF 5x

Granules India Share Price Live Chart

1 Day

(1.12%)

No Result Found

Summary

  • Market Cap (in Cr)

    19137.36

  • Net Profit (in Cr)

    501.52

  • P/B

    3.18

  • Sector P/E

    33.76

  • P/E

    23.55

  • EV/EBITDA

    12.81

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    14.45

  • ROCE

    15.61

  • Debt/Equity

    0.40

  • EPS (TTM)

    24.32

  • Dividend Yield

    0.23

  • Book Value

    205.21

  • Interest Cover

    7.39

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (13.2x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (12x coverage).
  • Dividends per share have been stable in the past 10 years.
  • Granules India's earnings growth is expected to exceed the low risk savings rate of 7.2%.
thumbs up icon

Cons

  • Granules India's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Granules India's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Granules India is expected to decrease over the next 2 years.
  • Granules India's earnings are expected to grow by 16.9% yearly, however this is not considered high growth (20% yearly).
  • Granules India's earnings growth is positive but not above the India market average.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters38.0238.8238.8238.8238.84
FII15.3113.5514.0913.2415.15
DII17.0117.4817.9222.7422.45
Public29.6630.1529.1725.2023.57
Government00000

Read More

Technical Analysis

RSI

66.80

MACD

12.28

50 DMA

858.71

200 DMA

697.69

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic979.50910.70869.60841.90800.80773.10704.30
Fibonacci910.70884.42868.18841.90815.62799.38773.10
Camarilla847.42841.11834.81841.90822.19815.89809.58

Pivots Level: Classic

R3

+137.60

979.50

R2

+68.80

910.70

R1

+27.70

869.60

841.90
841.90
Pivot Point
LTP: 909.30

S1

-41.10

800.80

S2

-68.80

773.10

S3

-137.60

704.30

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    875.51

  • 20-EMA

    863.38

  • 30-EMA

    857.25

  • 50-EMA

    843.73

  • 100-EMA

    799.86

  • 200-EMA

    727.57

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
29 Apr 2026agm
29 Apr 2026dividend₹1.75 Dividend /Share30 Jul 2026
29 Apr 2026board-meetingsAccounts, Quarterly Results, Final Dividend
23 Jan 2026board-meetingsQuarterly Results
23 Dec 2025egm
13 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
01 Jul 2025dividendFinal Dividend - Rs. - 1.531 Jul 2025
28 May 2025dividend₹1.50 Dividend /Share31 Jul 2025
28 May 2025agm
30 Jun 2024dividendAnnual General Meeting/Dividend - Rs 1.50 Per Share31 Jul 2024

Read More

Peer Comparison

Granules India Ltd logo

Granules India Ltd

Cipla Ltd logo

Cipla Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

Granules India Ltd About

Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs).(Source : 202503-Annual Report Page No:134)

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1991

Headquarters

CEO

C Krishna Prasad

Employees

Contact

Website icon

Website

http://www.granulesindia.com

Email icon

Email

investorrelations@granulesindia.com; mail@granules

Phone icon

Phone

91-40-69043500

Location icon

Location

15th Floor Granules Tower, Botanical Garden Road Kondapur, Hyderabad, Telangana, 500084

Read More

Granules India Ltd Company History

YearHistory
2020
  • Granules India arm got USFDA nod for Valganciclovir hydrochloride oral solution.
  • Granules India received USFDA approval for Colchicine Tablets.
  • Granules Pharmaceuticals Inc. got USFDA nod for Colchicine tablets.
  • Granules India got tentative USFDA nod for Colchicine capsules for gout.
  • Granules India got tentative nod from USFDA for expectorant tablets.
2021
  • Granules got USFDA nod for diabetes management drug.
  • Granules India got USFDA nod for generic low blood potassium treatment capsules.
  • Granules India received USFDA approval for Acetaminophen, Aspirin and Caffeine Tablets.
  • Granules India received USFDA approval for Dofetilide capsules.
  • Granules India's US unit got two observations from USFDA.
2022
  • Granules India received licenses from MPP to market Nirmatrelvir and Ritonavir.
  • Granules Pharmaceuticals Inc. received ANDA approval for Bupropion Hydrochloride Extended-Release Tablets.
  • Granules Pharmaceuticals Inc. received ANDA approval for Potassium Chloride for Oral Solution USP, 20 mEq.
2023
  • Granules India received USFDA approval for Losartan Potassium Tablets.
  • Granules India forged a strategic partnership with Greenko ZeroC.
2024
  • Granules India Limited was honored with the Golden Peacock Award for Sustainability.
  • Granules India received approval from the US health regulator to market a generic medication to treat major depressive disorder.
  • The company received approval from the US Food & Drug Administration for Bupropion Hydrochloride extended-release tablets USP (SR) in strength of 100 mg, 150 mg, and 200 mg.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
L7 HITECH PRIVATE LIMITEDbulkBuy171737587.4114 Jan 2025
L7 HITECH PRIVATE LIMITEDbulkSell1546000577.8514 Jan 2025
FIDELITY INDIA FUNDblockSell199081596.0220 Dec 2024
EDELWEISS MUTUAL FUNDblockBuy33500059620 Dec 2024
KOTAK MAHINDRA LIFE INSURANCE COMPANY LIMITEDblockBuy30000059620 Dec 2024
PAULOMI KETANKUMAR DOSHIblockBuy738285596.120 Dec 2024
ITI MUTUAL FUNDblockBuy50374159620 Dec 2024
BANDHAN MUTUAL FUNDblockBuy28696359620 Dec 2024
SBI LIFE INSURANCE COMPANY LIMITEDblockBuy50000059620 Dec 2024
BANDHAN MUTUAL FUNDblockBuy28601159620 Dec 2024

Read More

Granules India Ltd News

Granules India promoter sells 6.94% stake

Promoter Dr. Krishna Prasad Chigurupati sold 1.72 crore shares via block deal on September 11, 2026. The sale reduces his holding to 24.06% from 31.00%. Institutional investors participated.

12 Sept 2026

companies

Granules India schedules investor meet on Sep 18

Granules India Limited will host analysts and investors in Hyderabad on September 18, 2026. The meeting follows SEBI LODR Regulation 30 compliance. No unpublished price-sensitive information is expected to be shared during the session.

11 Sept 2026

companies

Granules India Q1FY27 PAT up 60% to INR 1,800 Mn

Granules India reported Q1FY27 revenue of INR 14,768 Mn, up 22% YoY. PAT rose 60% to INR 1,800 Mn with EBITDA at INR 3,389 Mn.

21 Jul 2026

companies

Granules India FY26: Revenue Hits ₹53,656 Mn, Up 20%

Granules India crossed the ₹50,000 million revenue milestone in FY 2025-26, with consolidated revenue of ₹53,656 million, EBITDA of ₹11,851 million, and PAT of ₹5,950 million, up 19% YoY.

15 Jul 2026

companies

Granules India: ₹16.49 Cr Block Trade on NSE

Granules India Ltd. recorded a block trade on NSE worth ₹16.49 crores, involving approximately 185,143 shares at a price of ₹890.90 per share.

09 Jul 2026

equity-markets

Read More

Frequently Asked Questions

  • 1.What is the stock price of Granules India Ltd?

    As of 15/09/2026 at 12:45 AM, Granules India Ltd shares are trading at ₹909.30.

  • 2.What is the market cap. of Granules India Ltd?

    As of 15/09/2026, the market capitalization of Granules India Ltd is ₹22,338.89 crore.

  • 3.When was Granules India Ltd founded?

    Granules India Ltd was founded in 1991.

  • 4.What are the P/E and P/B ratios of Granules India Ltd?

    As of 15/09/2026, Granules India Ltd has a P/E ratio of 33.78 and a P/B ratio of 3.18.

  • 5.How can I buy shares of Granules India Ltd?

    You can buy shares of Granules India Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Granules India Ltd?

    As of March,2026, promoters hold 38.02% in Granules India Ltd, while FIIs, DIIs and public shareholders hold 15.31%, 17.01% and 29.66%, respectively.

  • 7.Does Granules India Ltd pay dividends?

    Yes, Granules India Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹₹1.75 Dividend /Share per share.

  • 8.What is the dividend yield of Granules India Ltd?

    As of 15 September, 2026, the dividend yield of Granules India Ltd stands at 0.19%.

  • 9.What are the latest financial results of Granules India Ltd?

    For January,2024, Granules India Ltd reported revenue of ₹4,482.00 crore and a net profit of ₹502.00 crore.

  • 10.What is the Stock symbol of Granules India Ltd?

    GRANULES is the stock symbol of Granules India Ltd.

  • 11.Who is the CEO of Granules India Ltd?

    The CEO of Granules India Ltd is C Krishna Prasad.

Open Your Free Demat Account

Enter your phone number